Drug Development for Pediatric Populations: Regulatory Aspects

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2016 Oct 11

PMID 27721363

Citations 31

Authors

Jochen Zisowsky

Andreas Krause

Jasper Dingemanse

Affiliations

Soon will be listed here.

Abstract

Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in an increased number of trials in children. Specific guidelines and requirements from, in particular, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) form the regulatory framework. This review summarizes the regulatory requirements and strategies for pediatric drug development from an industry perspective. It covers pediatric study planning and conduct, considerations for first dose in children, appropriate sampling strategies, and different methods for data generation and analysis to generate knowledge about the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug in children. The role of Modeling and Simulation (M&S) in pediatrics is highlighted-including the regulatory basis-and examples of the use of M&S are illustrated to support pediatric drug development.

Citing Articles

A matrix tool to foster patient engagement in children, adolescents and young adults: report from a multistakeholder workshop.

Cavaller-Bellaubi M, Degraeuwe E, Walle J, Gasthuys E, Prytula A Res Involv Engagem. 2024; 10(1):125.

PMID: 39604985 PMC: 11600809. DOI: 10.1186/s40900-024-00658-z.

Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine.

Sutherland L, Carter L Heliyon. 2024; 10(12):e32597.

PMID: 39183838 PMC: 11341330. DOI: 10.1016/j.heliyon.2024.e32597.

Pediatric Formulations Developed by Extrusion-Based 3D Printing: From Past Discoveries to Future Prospects.

Ianno V, Vurpillot S, Prillieux S, Espeau P Pharmaceutics. 2024; 16(4).

PMID: 38675103 PMC: 11054634. DOI: 10.3390/pharmaceutics16040441.

State of the art in pediatric nanomedicines.

Abedin S, Adeleke O Drug Deliv Transl Res. 2024; 14(9):2299-2324.

PMID: 38324166 DOI: 10.1007/s13346-024-01532-x.

Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease.

Tiraboschi G, Marchionni D, Tuffal G, Fabre D, Martinez J, Haack K J Pharmacokinet Pharmacodyn. 2023; 50(6):461-474.

PMID: 37535240 PMC: 10673948. DOI: 10.1007/s10928-023-09874-8.

References

Edginton A, Schmitt W, Voith B, Willmann S . A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006; 45(7):683-704. DOI: 10.2165/00003088-200645070-00004. View

Bartelink I, Rademaker C, Schobben A, van den Anker J . Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006; 45(11):1077-97. DOI: 10.2165/00003088-200645110-00003. View

Kuczmarski R, Ogden C, Guo S, Grummer-Strawn L, Flegal K, Mei Z . 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002; (246):1-190. View

Laer S, Barrett J, Meibohm B . The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol. 2009; 49(8):889-904. DOI: 10.1177/0091270009337513. View

Manolis E, Pons G . Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol. 2009; 68(4):493-501. PMC: 2780274. DOI: 10.1111/j.1365-2125.2009.03484.x. View

Blumer J . Off-label uses of drugs in children. Pediatrics. 1999; 104(3 Pt 2):598-602. View

Roy A, Ette E . A pragmatic approach to the design of population pharmacokinetic studies. AAPS J. 2005; 7(2):E408-20. PMC: 2750978. DOI: 10.1208/aapsj070241. View

Jadhav P, Kern S . The need for modeling and simulation to design clinical investigations in children. J Clin Pharmacol. 2010; 50(9 Suppl):121S-129S. DOI: 10.1177/0091270010376968. View

Dingemanse J, Appel-Dingemanse S . Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet. 2007; 46(9):713-37. DOI: 10.2165/00003088-200746090-00001. View

10.

Bjorkman S . Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005; 59(6):691-704. PMC: 1884855. DOI: 10.1111/j.1365-2125.2004.02225.x. View

11.

Anderson B, Allegaert K, Holford N . Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006; 165(11):741-6. DOI: 10.1007/s00431-006-0188-y. View

12.

DArgenio D . Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981; 9(6):739-56. DOI: 10.1007/BF01070904. View

13.

Meibohm B, Laer S, Panetta J, Barrett J . Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005; 7(2):E475-87. PMC: 2750985. DOI: 10.1208/aapsj070248. View

14.

de Cock R, Piana C, Krekels E, Danhof M, Allegaert K, Knibbe C . The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2010; 67 Suppl 1:5-16. PMC: 3082690. DOI: 10.1007/s00228-009-0782-9. View

15.

Jadhav P, Zhang J, Gobburu J . Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. Pharm Stat. 2009; 8(3):216-24. DOI: 10.1002/pst.394. View

16.

Alcorn J, McNamara P . Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002; 41(12):959-98. DOI: 10.2165/00003088-200241120-00003. View

17.

Aarons L . Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol. 2005; 60(6):581-3. PMC: 1884881. DOI: 10.1111/j.1365-2125.2005.02560.x. View

18.

Bjorkman S . Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?. Clin Pharmacokinet. 2006; 45(1):1-11. DOI: 10.2165/00003088-200645010-00001. View

19.

Auby P . Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: an industry perspective. Child Adolesc Psychiatry Ment Health. 2008; 2(1):38. PMC: 2629463. DOI: 10.1186/1753-2000-2-38. View

20.

Gobburu J . Pharmacometrics 2020. J Clin Pharmacol. 2010; 50(9 Suppl):151S-157S. DOI: 10.1177/0091270010376977. View